Market research
HBP.TO Helix BioPharma Corp
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 150M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- -0.35
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA4229101098
- Market cap
- 150M
- P/E ratio
- Not available
- Analyst target
- 2.5
- Dividend yield
- Not available
- Beta
- -0.35
About
About Helix BioPharma Corp
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HBP.TO discussion.
5 years, 4 months ago
Helix BioPharma Corp is currently in a long term uptrend where the price is trading 36.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Helix BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 11.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Helix BioPharma Corp gets an overall score of 2/5.